GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AtriCure Inc (NAS:ATRC) » Definitions » EV-to-EBIT

AtriCure (AtriCure) EV-to-EBIT

: -46.62 (As of Today)
View and export this data going back to 2005. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, AtriCure's Enterprise Value is $1,068.7 Mil. AtriCure's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-22.9 Mil. Therefore, AtriCure's EV-to-EBIT for today is -46.62.

The historical rank and industry rank for AtriCure's EV-to-EBIT or its related term are showing as below:

ATRC' s EV-to-EBIT Range Over the Past 10 Years
Min: -120.96   Med: -34   Max: 78.4
Current: -46.62

During the past 13 years, the highest EV-to-EBIT of AtriCure was 78.40. The lowest was -120.96. And the median was -34.00.

ATRC's EV-to-EBIT is ranked worse than
100% of 465 companies
in the Medical Devices & Instruments industry
Industry Median: 19.09 vs ATRC: -46.62

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. AtriCure's Enterprise Value for the quarter that ended in Dec. 2023 was $1,633.4 Mil. AtriCure's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-22.9 Mil. AtriCure's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -1.40%.


AtriCure EV-to-EBIT Historical Data

The historical data trend for AtriCure's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AtriCure Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -41.57 -54.55 57.07 -49.01 -71.26

AtriCure Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -49.01 -59.59 -106.49 -113.37 -71.26

Competitive Comparison

For the Medical Instruments & Supplies subindustry, AtriCure's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AtriCure EV-to-EBIT Distribution

For the Medical Devices & Instruments industry and Healthcare sector, AtriCure's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where AtriCure's EV-to-EBIT falls into.



AtriCure EV-to-EBIT Calculation

AtriCure's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1068.691/-22.922
=-46.62

AtriCure's current Enterprise Value is $1,068.7 Mil.
AtriCure's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AtriCure  (NAS:ATRC) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

AtriCure's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-22.922/1633.41194
=-1.40 %

AtriCure's Enterprise Value for the quarter that ended in Dec. 2023 was $1,633.4 Mil.
AtriCure's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AtriCure EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of AtriCure's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


AtriCure (AtriCure) Business Description

Traded in Other Exchanges
N/A
Address
7555 Innovation Way, Mason, OH, USA, 45040
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.
Executives
Karl S. Dahlquist officer: Chief Legal Officer 7555 INNOVATION WAY, MASON OH 45040
Karen Prange director 1108 S RIO VISTA BLVD, FORT LAUDERDALE FL 33316
Maggie Yuen director ONE PENUMBRA PLACE, ALAMEDA CA 94502
Vinayak Doraiswamy officer: Chief Scientific Officer 7555 INNOVATION WAY, MASON OH 45040
Deborah Lee Yount officer: Chief Human Resources Officer 7555 INNOVATION WAY, MASON OH 45040
Tonya Austin officer: Chief Human Resources Officer 7555 INNOVATION WAY, MASON OH 45040
Angela L Wirick officer: Chief Financial Officer 7555 INNOVATION WAY, MASON OH 45040
Mark A Collar director 382 BISHOPBRIDGE DR, CINCINNATI OH 45255
Regina E Groves director 5751 COPLEY DRIVE, SAN DIEGO CA 92111
Douglas J Seith officer: SVP of Sales and Marketing 7555 INNOVATION WAY, MASON OH 45040
Salvatore Privitera officer: VP; Product Development 7555 INNOVATION WAY, MASON OH 45040
Justin J Noznesky officer: SVP, Mktg & Business Develop 7555 INNOVATION WAY, MASON OH 45040
Deborah H Telman director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Scott William Drake director 9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Sven Wehrwein director